XOMA (NASDAQ:XOMA) Upgraded to "Hold" at StockNews.com

XOMA (NASDAQ:XOMA - Get Free Report) was upgraded by StockNews.com from a "sell" rating to a "hold" rating in a report released on Tuesday.

Separately, HC Wainwright dropped their price target on shares of XOMA from $123.00 to $104.00 and set a "buy" rating on the stock in a research note on Monday, February 3rd.

XOMA Trading Down 1.1 %

Shares of XOMA stock traded down $0.30 during mid-day trading on Tuesday, reaching $26.76. The company's stock had a trading volume of 16,124 shares, compared to its average volume of 50,754. XOMA has a 12-month low of $20.51 and a 12-month high of $35.00. The firm has a market capitalization of $315.23 million, a PE ratio of -7.69 and a beta of 0.90. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. The company's 50 day simple moving average is $26.68 and its 200-day simple moving average is $27.95.

Insider Buying and Selling

In related news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of XOMA stock in a transaction on Friday, January 24th. The shares were sold at an average price of $26.10, for a total transaction of $13,069,366.20. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 7.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On XOMA

Several hedge funds and other institutional investors have recently modified their holdings of XOMA. BNP Paribas Financial Markets increased its position in shares of XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company's stock worth $43,000 after purchasing an additional 795 shares during the last quarter. New York State Common Retirement Fund increased its position in shares of XOMA by 51.2% in the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company's stock worth $62,000 after purchasing an additional 800 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of XOMA by 38.0% in the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company's stock worth $113,000 after purchasing an additional 1,183 shares during the last quarter. Los Angeles Capital Management LLC bought a new stake in shares of XOMA in the 4th quarter worth about $206,000. Finally, Rhumbline Advisers increased its position in shares of XOMA by 18.1% in the 4th quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company's stock worth $291,000 after purchasing an additional 1,699 shares during the last quarter. Institutional investors own 95.92% of the company's stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.